Success Metrics

Clinical Success Rate
86.7%

Based on 13 completed trials

Completion Rate
87%(13/15)
Active Trials
0(0%)
Results Posted
54%(7 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_1
10
56%
Ph phase_2
5
28%
Ph phase_3
3
17%

Phase Distribution

10

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
10(55.6%)
Phase 2Efficacy & side effects
5(27.8%)
Phase 3Large-scale testing
3(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.2%

13 of 18 finished

Non-Completion Rate

27.8%

5 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(13)
Terminated(5)

Detailed Status

Completed13
Withdrawn3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
86.7%
Most Advanced
Phase 3

Trials by Phase

Phase 110 (55.6%)
Phase 25 (27.8%)
Phase 33 (16.7%)

Trials by Status

completed1372%
terminated211%
withdrawn317%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT03459222Phase 1

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Completed
NCT02658890Phase 1

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Completed
NCT02935634Phase 2

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Completed
NCT03519256Phase 2

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Terminated
NCT02996110Phase 2

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Completed
NCT03792750Phase 1

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Completed
NCT03329846Phase 3

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Completed
NCT02750514Phase 2

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Terminated
NCT04007588Phase 2

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Withdrawn
NCT03936374Phase 1

A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants

Completed
NCT03386838Phase 3

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Withdrawn
NCT03192943Phase 1

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Completed
NCT03374228Phase 1

A Study to Evaluate the Bioavailability of BMS-986205

Completed
NCT03417037Phase 3

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Withdrawn
NCT03346837Phase 1

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

Completed
NCT03362411Phase 1

A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet

Completed
NCT03312426Phase 1

An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants

Completed
NCT03247283Phase 1

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18